A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Bartlett, NL; Herrera, AF; Domingo-Domenech, E; Mehta, A; Forero-Torres, A; Garcia-Sanz, R; Armand, P; Devata, S; Izquierdo, AR; Lossos, IS; Reeder, C; Sher, T; Chen, R; Schwarz, SE; Alland, L; Strassz, A; Prier, K; Choe-Juliak, C; Ansell, SM

Ansell, SM (corresponding author), Mayo Clin, Div Hematol, 200 First St SW, Rochester, MN 55905 USA.

BLOOD, 2020; 136 (21): 2401

Abstract

In relapsed/refractory Hodgkin lymphoma (R/R HL), immunotherapies such as the anti-programmed death-1 inhibitor pembrolizumab have demonstrated effica......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索